Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma

British Journal of Cancer

Volumn 78, Issue 4, 1998, Pages 528-533

  Pession, A ^a   Prete, A ^a   Locatelli, F ^b   Pierinelli, S ^a   Pession, A L ^c   Maccario, R ^b   Magrini, E ^a   De Bernardi, B ^d   Paolucci, P ^e   Paolucci, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

High dose chemotherapy; Immunotherapy; Interleukin 2; Neuroblastoma

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; INTERLEUKIN 2; MELPHALAN; RECOMBINANT INTERLEUKIN 2; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILDHOOD CANCER; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; KILLER CELL; MALE; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WHOLE BODY RADIATION;

EID: 7344238494     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.527     Document Type: Article

References (24)

1. Bilgrami S, Silva M, Cardoso A, Miller KB and Ascensao JL (1994) Immunotherapy with autologous bone marrow transplantation: rationale and results. Exp Hematol 22: 1039-1050
2. Brodeur GM, Seeger RC, Barret A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI, Haase G, Hartman O, Hayes FA, Helson L, Kemshead J, Lampert F, Ninane J, Ohakawa H, Philip T, Pinkerton CR, Pritchard J, Sawada T, Siegel S and Smith EI (1988) International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6: 1874-1881
3. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrol M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee REJ, Look ADJ, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y and Voute PA (1993) Revision of international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466-1477
4. Dini G, Lanino E, Garaventa A, Pasino M, Rivabella L, Boni L, Marchese N, Ivani G, Rizo A, Franzone P, Trasino S and De Bernardi B (1991) Myeloablative tharapy and unpurged autologous bone marrow transplantation for poor prognosis neuroblastoma: report of 34 cases. J Clin Oncol 9: 962-969
5. Donfrancesco A, Deb G, Dominici C, Angioni A, Caniglia M, De Sio L, Fidani P, Amici A and Helson L (1992) Deferoxamine, cyctophosphamide, etoposide, carboplatin and thiolepa (D-CECaT): a new cytoreductive-chelation therapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol 15: 319-322
6. Favrot MC, Floret D, Negrier S, Cochat P, Bouffet E, Zhou DC, Franks CR, Bijman T, Brunat-Mentigny M, Philip I and Philip T (1989) Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant 4: 499-503
7. Garaventa A, Rondelli R, Lanino E, Dallorso S, Dini G, Bonetti F, Arrighini A, Santoro N, Rossetti F, Miniero R, Andolina A, Amici A, Indolfi P, Lo Curto M, Favre C, Paolucci P, Pession A and De Bernardi B (1996) Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry, Bone Marrow Transplant 18: 125-130
8. Guarini A, Sanavio F, Novarino A, Gillio TA, Aglietta M and Foa R (1991) Thrombocytopenia in acute leukemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors. Br J Haematol 79: 451-456
9. Hayes FA and Smith EI (1989) Neuroblastoma. In Principles and Practice of Pediatric Oncology, Pizzo PA and Poplack DG, (eds), pp. 607-622. JB Lippincott: Philadelphia
10. Hercend T, Meuer S, Reinherz EL, Schlossman SF and Ritz. J (1982) Generation of a cloned NK cell line derived from the 'null cell' fraction of human peripheral blood. J Immunol 129: 1299-1305
11. Higuchi CM, Thompson JM, Cox T, Lindgren CG, Buckner CD and Fefer A (1989) Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res 49: 5509
12. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observation. J Am Statist Assoc 53: 457-481
13. Ladenstein R, Lasset C, Hartmann O, Zucker JM, Garaventa A, Pearson A, Pinkerton R, Coze C, Gadner H, Klingebiel T, Paolucci P, Kremens B and Philip T (1994) Analysis of European experience with megatherapy (MGT) and BMT in advanced neuroblastoma (NBL). A final report of the EBMT Solid Tumour Registry, In Proceedings of the XXVIth Meeting of the International Society of Paediatric Oncology (SIOP). ABMT in Solid Tumour Symposium. Hartmann O and Pinkerton R. (eds), pp. 10-11, 20-24 September 1994, Paris, France
14. Main EK, Lampson LA, Hart MK, Kornbluth J and Wilson DB (1985) Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes. J Immunol 135: 242-246
15. Main EK, Monos DS and Lampson LA (1988) IFN-treated neuroblastoma cell lines remain resistant to T cell-mediated allo-killing, and susceptible to non-MHC-restricted cytotoxicity. J Immunol 141: 2943-2950
16. Martì F, Pardo N, Peirò M, Bertran E, Amill B, Garcia J, Cubells J and Rueda F (1995) Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation. Exp Haematol 23: 1445-1452
17. Negrier S, Michon MD, Floret D, Bouffet E, Gentet JC, Philip I, Cochat P, Stamm D, Costil J, Gaspard M, Andreu G, Palmer P, Franks CR, Zucker JM, Brernard JL, Fridman WH, Favrot M and Philip T (1991) Interleukin-2 and lymphokine activated cells in 15 children with advanced metastatic neuroblastoma. J Clin Oncol 9: 1363-1370
18. Paciucci PA, Mandeli J, Olcksowiz L, Ameglio F and Holland JF (1990) Thrombocytopenia during immunotherapy with interleukin-2 by constant infusion. Am J Med 89: 308-312
19. Pardo N, Marti F, Fraga G, Illa J, Badell I, Peirò M, Bertran E, Garcia J, Rueda F and Cubells J (1996) High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. Med Pediatr Oncol 27: 534-539
20. Seeger RC, Villablanca JG, Matthay KK, Harris R, Moss TJ, Feig SA, Selch M, Ramsay N and Reynolds CP (1991) Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma Prog Clin Biol Res 366: 527-533
21. Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Shuman WP, Levitt D and Fefer A (1990) Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res 49: 235-240
22. Valteau-Couanet D, Rubie H, Meresse V, Farace F, Brandely M and Hartmann O (1995) Phase I-II study of interleukin-2 after high dose chemotherapy and autologus bone marrow transplantation in poorly responding neuroblastoma. Bone Marrow Transplant 16: 515-520
23. Welte K, Ciobanu N and Moore M (1994) Defective interleukin-2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin-2. Blood: 64: 380
24. Zhang SR, Urias PE, Twilley TA, Talmadge JE, Herberman RB and Wiltrout RH (1986) Augmentation of liver-associated NK activity and macrophage-mediated cytotoxicity following administration of biological response modifiers. Cancer Immunol Immunother 21: 19-25